Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: Retrospective analysis of the phase iii extreme trial

Annals of Oncology

Volumn 25, Issue 4, 2014, Pages 801-807

  Vermorken, J B ^a   Psyrri, A ^b   Mesia R ^c   Peyrade, F ^d   Beier, F ^e   De Blas, B ^e   Celik, I ^e   Licitra, L ^f  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d CENTRE ANTOINE LACASSAGNE   (France)

^e MERCK KGAA   (Germany)

^f NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cetuximab; Human papillomavirus; P16; Recurrent and metastatic; Squamous cell carcinoma of the head and neck

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DNA EXTRACTION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; WART VIRUS; CARCINOMA, SQUAMOUS CELL; DISEASE FREE SURVIVAL; GENETICS; HEAD AND NECK NEOPLASMS; ISOLATION AND PURIFICATION; METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAPILLOMA VIRUS; PATHOGENICITY; PATHOLOGY; PROGNOSIS; VIROLOGY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRIDAE; PROGNOSIS;

EID: 84897101976     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt574     Document Type: Article

References (19)

1. Rampias T, Sasaki C, Weinberger P et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009;101:412-423.
2. Mehanna H, Beech T, Nicholson T et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck 2013;35:747-755.
3. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
4. Isayeva T, Li Y, Maswahu D et al. Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol 2012;6 (Suppl 1): S104-S120.
5. Vermorken J, Stöhlmacher J, Oliner K et al. Safety and efficacy of panitumumab (pmab) in HPV positive (+) and HPV negative (-) recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): analysis of the phase 3 SPECTRUM trial. Eur J Cancer 2011;47(Suppl 2):13LBA.
6. Weinberger PM, Yu Z, Haffty BG et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24:736-747.
7. Vermorken JB, Stohlmacher-Williams J, Davidenko I et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013;14:697-710.
8. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
9. Chaturvedi AK, Engels EA, Anderson WF et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-619.
10. Licitra L, Zigon G, Gatta G et al. Human papillomavirus in HNSCC: a European epidemiologic perspective. Hematol Oncol Clin North Am 2008;22:1143-1153, vii-viii.
11. Kreimer AR, Clifford GM, Boyle P et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-475
12. Herrero R, Castellsague X, Pawlita M et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95:1772-1783.
13. Mehra R, Egloff AM, Li S et al. Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol 2013;31(suppl): (abstr 6006).
14. Kurai J, Chikumi H, Hashimoto K et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007;13:1552-1561.
15. Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007;133:1277-1281.
16. Schneider-Merck T, Lammerts van Bueren JJ, Berger S et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibodydependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010;184:512-520.
17. Rampias T, Pectasides E, Prasad M et al. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype. Ann Oncol 2013;24:2124-2131.
18. Guo M, Dhillon J, Khanna A et al. Cervista HPV HR and HPV16/18 assays in head and neck FNA specimens, a valid option of HPV testing, compared with HPV in situ hybridization/p16 immunostaining assays in tissue specimens. J Am Soc Cytopathol 2012;1: S71 (abstr 124).
19. Khanna A, Patel S, Feng J et al. Validation of Cervista HPV HR and Cervista HPV16/18 assays in head and neck FNA specimens from patients with oropharyngeal carcinoma. J Am Soc Cytopathol 2012;1: S71 (abstr 125)